Fate Therapeutics (FATE)
(Real Time Quote from BATS)
$1.08 USD
+0.02 (1.89%)
Updated Aug 5, 2025 03:48 PM ET
3-Hold of 5 3
F Value C Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
FATE 1.08 +0.02(1.89%)
Will FATE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FATE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FATE
Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report?
Top Cancer Stocks to Supercharge Your 2025 Portfolio
FATE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag
Other News for FATE
Redmile Group, LLC Increases Stake in Fate Therapeutics Inc
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | ...
FATE: Analyst Maintains Hold Rating on Fate Therapeutics | FATE Stock News
Fate Therapeutics (FATE) Receives a Hold from TD Cowen
Cautious Hold on Fate Therapeutics: Promising Early Data for FT819 in Lupus, Awaiting Broader Evidence